# A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatob

Source: https://onco.cc/trials/nct07769502/  
OnCo record `nct07769502` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of telisotuzumab adizutecan, gemcitabine and nab-paclitaxel in pancreatic cancer, run by AbbVie, now recruiting.

## Summary

A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers is a phase 2, randomised interventional study registered as NCT07769502 by AbbVie, with a registry enrolment figure of 168 participants, started 2026-08-17 and due to reach its primary completion in 2028-09. Interventions recorded: Telisotuzumab Adizutecan; Gemcitabine; Nab-Paclitaxel. Conditions listed: Pancreatobiliary Cancers; Pancreatic Ductal Adenocarcinoma. Primary outcome: Overall Response (OR) Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; Number of Participants with Adverse Events (AEs). Sites: Israel, Japan, Taiwan. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07769502
- Phase: 2
- Setting: A Phase 2, Open-Label, Master Protocol Study to Evaluate Safety and Efficacy of Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Pancreatobiliary Cancers (AndroMETa-118)
- Sponsor: AbbVie
- Enrolled: 168

## Sources

- ClinicalTrials.gov NCT07769502: https://clinicaltrials.gov/study/NCT07769502

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [Telisotuzumab adizutecan](https://onco.cc/drugs/telisotuzumab-adizutecan/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07769502.json